SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:
| Jones Healthcare and Technology Innovation Conference | ||
| Location: | Las Vegas, NV | |
| Date: | Wednesday, 9 April 2025 | |
| Time: | 4:30 pm ET | |
| The Citizens Life Sciences Conference | ||
| Location: | New York, NY | |
| Date: | Thursday, 8 May 2025 | |
| Time: | 1:00 pm ET | |
| Jefferies Global Healthcare Conference | ||
| Location: | New York, NY | |
| Date: | Wednesday & Thursday, 4 & 5 June 2025 | |
Additional information for the Jefferies presentation will be made available closer to the conference on the Events page within the Investors & Media section of Immutep’s website.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Sodali & Co.
+61 (0)406 759 268; catherine.strong@sodali.com
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
| Last Trade: | US$1.85 |
| Daily Change: | -0.01 -0.54 |
| Daily Volume: | 145,114 |
| Market Cap: | US$269.100M |
April 29, 2025 March 25, 2025 March 20, 2025 January 22, 2025 December 17, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
